Haplo HCT vs Haplo-cord HCT for Patients With AML

Inclusion Criteria: 1. Age 18 to 60 years old; 2. Patients with AML; 3. With available minimal residual disease (MRD) parameters assessed by flow cytometry (FCM) and/or quantitative real-time PCR (qPCR) 4. Having no available HLA-matched donor, and willing to undergo haplo-HCT and having a suitable haploidentical donor 5. With Eastern Cooperative Oncology Group (ECOG) performance status of 0-3 6. Signing informed consent form, having the ability to comply with study and follow-up procedures Exclusion Criteria: 1. Acute promyelocytic leukaemia (AML subtype M3) 2. With other malignances 3. Failing to acquire a suitable UCB unit 4. With previous history of autologous haematopoietic cell transplantation (auto-HCT), allogeneic haematopoietic cell transplantation (allo-HCT) or chimaeric antigen receptor T-cell therapy 5. With uncontrolled infection intolerant to haplo-HCT 6. With severe organ dysfunction * Cardiac dysfunction (particularly congestive heart failure, unstable coronary artery disease and serious cardiac ventricular arrhythmias requiring antiarrhythmic therapy) * Respiratory failure (PaO2≤60 mmHg) * Hepatic abnormalities (total bilirubin≥2×upper limit of normal \[ULN\], alanine aminotransferase or aspartate aminotransferase≥2×ULN) * Renal dysfunction (creatinine≥2 mg/dL creatinine clearance rate \< 30 mL/min) 7. In pregnancy or lactation period 8. With any conditions not suitable for the trial (investigators' decision)